Simcere Pharmaceutical Group Limited

Simcere Pharmaceutical Group Limited engages in the research development manufacture and sale of pharmaceutical products for distributors and pharmacy chains and other pharmaceutical manufacturers in China It focusses on various therapeutic areas including oncology central nervous system autoimmune antiinfection cardiovascular and others The companys principal products include Sanbexin an edaravone and dexborneol concentrated solution for injection Endostar a recombinant human endostatin injection ENWEIDA an envafolimab injection Softan a rosuvastatin calcium tablet ZAILIN an amoxicillin granulesdispersible tabletcapsule Iremod an iguratimod tablet Antine a diclofenac sodium sustained release capsulegel and Orencia an abatacept injection It also offers promotion services for pharmaceutical products Simcere Pharmaceutical Group Limited has a strategic regional licensing partnership with Vivoryon Therapeutics NV to develop and commercialize medicines targeting the neurotoxicity amyloid protein N3pE pGluAss to treat Alzheimers disease The company was founded in 1995 and is headquartered in Nanjing China